



Recombinant Protein Technical Manual
Recombinant Mouse PD-L1/B7-H1/CD274 Protein
(His & Fc Tag)(Active)
RPES4258

Product Data:

Product SKU: RPES4258

Size: 100µg

Species: Mouse

Expression host: HEK293 Cells

Uniprot: NP_068693.1

Protein Information:

Molecular Mass: 52.8 kDa

AP Molecular Mass: 65-75 kDa

Tag: C-His-Fc

Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized recombinant mouse PD at 10 µg/ml (100 µl/well) can bind biotinylated mouse PD-L1 with a linear range of 3.2-400 ng/ml.

Purity: > 97 % as determined by SDS-PAGE

Endotoxin: < 1.0 EU per µg of the protein as determined by the LAL method.

Storage: Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Application: Functional ELISA

Synonyms: Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1;PD-L1;PDCD1 ligand 1;programmed death ligand 1;B7 homolog 1;B7-H1;CD274;B7h1;Pcdcd1l1;Pcdcd1lg1;Pdl1

Immunogen Information:

Sequence: Met 1-Thr 238

Background:

Programmed death ligand (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death (PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.